|
Gene: DCAF5 |
Gene summary for DCAF5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DCAF5 | Gene ID | 8816 |
Gene name | DDB1 and CUL4 associated factor 5 | |
Gene Alias | BCRG2 | |
Cytomap | 14q24.1 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96JK2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8816 | DCAF5 | CA_HPV_1 | Human | Cervix | CC | 3.43e-02 | -6.69e-02 | 0.0264 |
8816 | DCAF5 | CCI_1 | Human | Cervix | CC | 8.05e-05 | 7.63e-01 | 0.528 |
8816 | DCAF5 | CCI_3 | Human | Cervix | CC | 3.90e-03 | 5.22e-01 | 0.516 |
8816 | DCAF5 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.34e-09 | -4.60e-01 | 0.0155 |
8816 | DCAF5 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.09e-02 | -3.77e-01 | 0.096 |
8816 | DCAF5 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.25e-12 | -3.60e-01 | 0.3859 |
8816 | DCAF5 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.93e-04 | -3.47e-01 | 0.3005 |
8816 | DCAF5 | A002-C-010 | Human | Colorectum | FAP | 3.67e-04 | -2.44e-01 | 0.242 |
8816 | DCAF5 | A001-C-207 | Human | Colorectum | FAP | 1.97e-03 | -3.27e-01 | 0.1278 |
8816 | DCAF5 | A015-C-203 | Human | Colorectum | FAP | 3.96e-27 | -4.90e-01 | -0.1294 |
8816 | DCAF5 | A015-C-204 | Human | Colorectum | FAP | 2.11e-09 | -4.37e-01 | -0.0228 |
8816 | DCAF5 | A014-C-040 | Human | Colorectum | FAP | 1.62e-03 | -4.90e-01 | -0.1184 |
8816 | DCAF5 | A002-C-201 | Human | Colorectum | FAP | 8.84e-14 | -3.93e-01 | 0.0324 |
8816 | DCAF5 | A002-C-203 | Human | Colorectum | FAP | 1.12e-04 | -2.29e-01 | 0.2786 |
8816 | DCAF5 | A001-C-119 | Human | Colorectum | FAP | 8.35e-06 | -3.70e-01 | -0.1557 |
8816 | DCAF5 | A001-C-108 | Human | Colorectum | FAP | 1.92e-18 | -4.04e-01 | -0.0272 |
8816 | DCAF5 | A002-C-205 | Human | Colorectum | FAP | 5.13e-21 | -5.29e-01 | -0.1236 |
8816 | DCAF5 | A001-C-104 | Human | Colorectum | FAP | 6.56e-06 | -3.57e-01 | 0.0184 |
8816 | DCAF5 | A015-C-005 | Human | Colorectum | FAP | 1.94e-03 | -2.60e-01 | -0.0336 |
8816 | DCAF5 | A015-C-006 | Human | Colorectum | FAP | 8.55e-14 | -4.28e-01 | -0.0994 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DCAF5 | SNV | Missense_Mutation | novel | c.2659N>A | p.Glu887Lys | p.E887K | Q96JK2 | protein_coding | tolerated_low_confidence(0.06) | benign(0.027) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DCAF5 | SNV | Missense_Mutation | novel | c.2273N>T | p.Pro758Leu | p.P758L | Q96JK2 | protein_coding | tolerated_low_confidence(0.73) | benign(0) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DCAF5 | SNV | Missense_Mutation | c.2741A>T | p.His914Leu | p.H914L | Q96JK2 | protein_coding | tolerated_low_confidence(0.27) | benign(0.04) | TCGA-B6-A0RO-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
DCAF5 | SNV | Missense_Mutation | c.2009C>T | p.Ser670Phe | p.S670F | Q96JK2 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
DCAF5 | SNV | Missense_Mutation | c.2488N>A | p.Ala830Thr | p.A830T | Q96JK2 | protein_coding | tolerated_low_confidence(0.65) | benign(0.001) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
DCAF5 | insertion | Frame_Shift_Ins | novel | c.1564_1565insTTGAGCAGTGCTGCAACATGTACTGTATGAAGGCCAT | p.Lys522IlefsTer21 | p.K522Ifs*21 | Q96JK2 | protein_coding | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
DCAF5 | deletion | Frame_Shift_Del | novel | c.2249delG | p.Ser750ThrfsTer22 | p.S750Tfs*22 | Q96JK2 | protein_coding | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
DCAF5 | deletion | Frame_Shift_Del | novel | c.2244_2247delGCAC | p.His749AlafsTer22 | p.H749Afs*22 | Q96JK2 | protein_coding | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
DCAF5 | SNV | Missense_Mutation | c.1385C>T | p.Ser462Leu | p.S462L | Q96JK2 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
DCAF5 | SNV | Missense_Mutation | c.1378G>C | p.Glu460Gln | p.E460Q | Q96JK2 | protein_coding | deleterious(0.02) | possibly_damaging(0.461) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |